<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Maralixibat: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Maralixibat: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Maralixibat: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="133174" href="/d/html/133174.html" rel="external">see "Maralixibat: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="133192" href="/d/html/133192.html" rel="external">see "Maralixibat: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56259320"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Livmarli</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58692602"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Livmarli</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56250232"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ileal Bile Acid Transporter Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F56328380"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a55f1102-731a-44c1-bfad-85de9d0042d3">Cholestatic pruritus due to Alagille syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholestatic pruritus due to Alagille syndrome: </b> Oral solution (9.5 <b>mg</b>/mL): <b>Oral: </b> Initial: 0.19 mg/kg/dose (maximum: 14.25 mg/dose) once daily for 7 days, then increase to target dose of 0.38 mg/kg/dose (maximum: 28.5 mg/dose) once daily. Maximum daily dose: 28.5 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Missed dose:</i> If &lt;12 hours from usual time, administer missed dose as soon as possible and return to original dosing schedule; if &gt;12 hours have elapsed, omit dose and resume dosing at original dosing schedule.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56328381"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56328382"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Baseline hepatic impairment: </b> There are no dosage adjustments provided in the manufacturer's labeling; patients with Alagille syndrome may have elevated liver enzymes as part of disease state; clinical trials included patients with baseline LFT elevations. Has not been studied in patients with significant portal hypertension or decompensated cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment during therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>New-onset liver test abnormalities (eg, ALT, AST, bilirubin [direct/total], INR): </i>Hold maralixibat therapy. If liver test abnormalities return to baseline or stabilize at a new baseline value (and no signs/symptoms of hepatitis or decompensation are present), may consider restarting at 0.19 mg/kg/dose (maximum: 14.25 mg/dose) once daily and increase as tolerated to 0.38 mg/kg/dose (maximum: 28.5 mg/dose) once daily. If liver test abnormalities recur, consider permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatic decompensation (eg, variceal hemorrhage, ascites, hepatic encephalopathy, symptoms consistent with clinical hepatitis):</i> Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Portal hypertension:</i> Discontinue permanently.</p></div>
<div class="block dot drugH1Div" id="F56328383"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea (persistent or accompanied by bloody stools), vomiting, dehydration requiring treatment, or fever: </b>Hold maralixibat. Once diarrhea, abdominal pain, and/or vomiting resolve, restart at 0.19 mg/kg/dose (maximum: 14.25 mg/dose) once daily and increase as tolerated to 0.38 mg/kg/dose (maximum: 28.5 mg/dose) once daily. If symptoms recur, consider discontinuation of maralixibat therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin deficiency (fat soluble):</b> If fat-soluble vitamin deficiency worsens or persists despite supplementation, consider discontinuation of maralixibat therapy.</p></div>
<div class="block dop drugH1Div" id="F56270578"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="133174" href="/d/html/133174.html" rel="external">see "Maralixibat: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a55f1102-731a-44c1-bfad-85de9d0042d3">Cholestatic pruritus due to Alagille syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholestatic pruritus due to Alagille syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: Oral solution (9.5 mg/mL): Oral: Initial: 0.19 mg/kg/dose once daily for 7 days (maximum initial daily dose: 14.25 mg<b>/day</b>) then increase to target dose of 0.38 mg/kg/dose once daily. Maximum maintenance daily dose: 28.5 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">GI toxicity:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Persistent diarrhea or diarrhea accompanied by bloody stools, vomiting, dehydration requiring treatment, or fever</i>: Hold maralixibat. Once diarrhea, abdominal pain, and/or vomiting resolve, restart at 0.19 mg/kg/dose once daily and increase as tolerated to 0.38 mg/kg/dose once daily. If recurs, consider discontinuation of maralixibat therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Other toxicity:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fat-soluble vitamin deficiency:</i> If occurs, supplement with deficient vitamin as appropriate. If deficiency worsens or persists despite adequate supplementation, consider discontinuation of maralixibat therapy.</p></div>
<div class="block dorp drugH1Div" id="F56270581"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F56270582"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥3 months, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i> There are no dosing adjustments provided in the manufacturer's labeling; patients with Alagille syndrome may have elevated liver enzymes as part of disease state; clinical trials included patients with baseline LFT elevations. Has not been studied in patients with significant portal hypertension or decompensated cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatic impairment during therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">New-onset liver test abnormalities (eg, ALT, AST, bilirubin [direct/total], INR): Hold maralixibat therapy until return to baseline or stabilized at a new baseline value. Consider restarting at 0.19 mg/kg/dose once daily and increase as tolerated to 0.38 mg/kg/dose. If liver test abnormalities recur, consider permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic decompensation (eg, variceal hemorrhage, ascites, hepatic encephalopathy, symptoms consistent with clinical hepatitis): Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">Portal hypertension: Discontinue permanently.</p></div>
<div class="block arsc drugH1Div" id="F56613958"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elevations of liver functions tests (LFTs) or worsening of LFTs may commonly occur. Hepatic abnormalities may include <b>increased serum alanine aminotransferase</b>, <b>increased serum aspartate aminotransferase</b>, and <b>increased serum bilirubin</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; in a clinical trial, serum alanine aminotransferase increased above baseline after &gt;1 year of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34755627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34755627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• History of persistent or recurrent LFT abnormalities</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea</b>, <b>abdominal pain</b>, and <b>vomiting</b> may commonly occur, leading to dehydration hospitalization. <b>Nausea</b> has also been reported frequently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<i>Mechanism: </i>Related to sequelae of bile acid malabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30288474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30288474'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; in one clinical trial, the majority of events occurred within the first four weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34755627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34755627'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vitamin deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fat-soluble vitamin (FSV) deficiency (including <b>vitamin A deficiency</b>, <b>vitamin D deficiency</b>, <b>vitamin E deficiency</b>, and <b>vitamin K deficiency</b>) may commonly occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action (ie, decreased absorption of FSVs).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56253774"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and young adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Vitamin deficiency (including vitamin A deficiency, vitamin D deficiency, vitamin E deficiency, vitamin K deficiency)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased INR</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic:<b></b>Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture</p></div>
<div class="block coi drugH1Div" id="F56250235"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to maralixibat or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F56328342"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F56270577"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F56259321"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Livmarli: 9.5 mg/mL (30 mL) [contains edetate (edta) disodium, propylene glycol]</p></div>
<div class="block geq drugH1Div" id="F56259319"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56316792"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Livmarli Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9.5 mg/mL (per mL): $2,136.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58692603"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Livmarli: 9.5 mg/mL (30 mL) [contains edetate (edta) disodium, propylene glycol]</p></div>
<div class="block adm drugH1Div" id="F56328384"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer in the morning 30 minutes before a meal; patient should be seated upright or standing; patient should remain upright for a few minutes after administration. Administer using calibrated oral dosing syringe; do not use a household teaspoon or other dosing device; for dose volumes ≤0.5 mL, use a 0.5 mL syringe; for dose volumes 0.6 to ≤1 mL, use a 1 mL syringe; for dose volumes &gt;1 mL, use 3 mL dosing syringe.</p></div>
<div class="block admp drugH1Div" id="F56270585"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer 30 minutes before a meal in the morning; patient should be seated upright or standing and should remain upright for a few minutes after administration. Administer using calibrated oral dosing syringe; do not use a household teaspoon or other dosing device; for dose volumes ≤0.5 mL, use a 0.5 mL syringe; for dose volumes 0.6 to ≤1 mL, use a 1 mL syringe; for dose volumes &gt;1 mL, use 3 mL dosing syringe.</p>
<p style="text-indent:-2em;margin-left:2em;">Missed dose: If &lt;12 hours from usual time, administer missed dose as soon as possible and return to original dosing schedule; if &gt;12 hours have elapsed, omit dose and resume dosing at original dosing schedule.</p></div>
<div class="block use drugH1Div" id="F56250234"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cholestatic pruritus due to Alagille syndrome:</b> Treatment of cholestatic pruritus in patients with Alagille syndrome ≥3 months (US labeling) or ≥12 months (Canadian labeling) of age.</p></div>
<div class="block cyt drugH1Div" id="F56284020"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56284017"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Maralixibat. Management: Bile acid sequestrants should be administered either at least 4 hours before, or 4 hours after, maralixibat.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F56328340"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Due to low systemic absorption following oral administration, potential fetal exposure is expected to be limited. Maternal use of maralixibat may decrease the absorption of fat-soluble vitamins; supplementation may be needed.</p></div>
<div class="block brc drugH1Div" id="F56328341"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if maralixibat is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to low systemic absorption following oral maternal administration, exposure to an infant via breast milk is expected to be limited. Maternal use of maralixibat may decrease the absorption of fat-soluble vitamins; supplementation may be needed. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56328386"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor liver function (ALT, AST, bilirubin [total/direct], INR) (baseline, periodically), fat-soluble vitamin serum concentrations; GI symptoms (diarrhea, vomiting).</p></div>
<div class="block pha drugH1Div" id="F56328345"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly inhibits the ileal bile acid transporter, decreasing the reabsorption of bile acids from the terminal ileum.</p></div>
<div class="block phk drugH1Div" id="F56328346"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 91%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (primary route; 94% as unchanged drug).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics (AAP) Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maralixibat-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34755627">
<a name="34755627"></a>Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. <i>Lancet</i>. 2021;398(10311):1581-1592. doi:10.1016/S0140-6736(21)01256-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maralixibat-drug-information/abstract-text/34755627/pubmed" id="34755627" target="_blank">34755627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Livmarli.1">
<a name="Livmarli.1"></a>Livmarli (maralixibat) [prescribing information]. Foster City, CA: Mirum Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Livmarli.2">
<a name="Livmarli.2"></a>Livmarli (maralixibat) [product monograph]. Foster City, CA: Mirum Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30288474">
<a name="30288474"></a>Shneider BL, Spino C, Kamath BM, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome. <i>Hepatol Commun</i>. 2018;2(10):1184-1198. doi:10.1002/hep4.1244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maralixibat-drug-information/abstract-text/30288474/pubmed" id="30288474" target="_blank">30288474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maralixibat-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maralixibat-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 133173 Version 36.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
